Quantitative response of macular neovascularisation to loading phase of aflibercept in neovascular age-related macular degeneration

被引:1
|
作者
Montesel, Andrea [1 ,2 ]
Hagag, Ahmed M. [1 ,2 ,3 ]
Chandra, Shruti [1 ,2 ,3 ]
Muhammed, Raheeba Pakeer [1 ,2 ]
Thottarath, Sridevi [1 ,2 ]
Chandak, Swati [1 ,2 ]
Sivaprasad, Sobha [1 ,2 ,3 ]
机构
[1] Moorfields Eye Hosp NHS Fdn Trust, NIHR Moorfields Biomed Res Ctr, 162 City Rd, London EC1V 2PD, England
[2] Moorfields Eye Hosp NHS Fdn Trust, Clin Res Facil, 162 City Rd, London EC1V 2PD, England
[3] UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England
关键词
COHERENCE TOMOGRAPHY-ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION; TYPE-3; NEOVASCULARIZATION; RETINA;
D O I
10.1038/s41433-023-02574-0
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PurposeTo evaluate quantitative morphological changes in macular neovascularisation (MNV) network after aflibercept therapy in neovascular age-related macular degeneration (nAMD) patients.MethodsConsecutive treatment-naive patients with optical coherence tomography (OCT) angiography confirmed MNV due to nAMD who completed a loading phase of intravitreal aflibercept injections. A quantitative analysis of the vascular network remodelling was performed using a computational software (Angiotool).ResultsA total of 53 eyes of 52 patients were included in the analysis. The total MNV area decreased significantly after three aflibercept injections (p = 0.003). Total vessel area and vessel density decreased respectively of 20% and 12% at V3 (p < 0.001 in both cases). Other parameters that reduced significantly were total vessel length, average vessel length and density of vascular junctions (p = 0.018, p = 0.002, and p = 0.044, respectively). The number of vascular endpoints (p = 0.001) and lacunarity (p = 0.011) increased significantly, whilst the number of vascular junctions did not vary significantly (p = 0.068). Changes in vascular metrics were predominantly driven by MNV type 1 and 2. No clear relationship was observed between any of the vascular metrics and the macular fluid status.ConclusionAlthough objective quantification of vascular parameters showed a significant remodelling of the MNV post-loading phase of aflibercept in type 1 and 2 MNV subtypes, none of the quantified vascular metrics correlated to the macular fluid response. These findings highlight a dissociation of anti-angiogenic and anti-permeability properties of aflibercept therapy during the loading phase.
引用
收藏
页码:3648 / 3655
页数:8
相关论文
共 50 条
  • [1] Quantitative response of macular neovascularisation to loading phase of aflibercept in neovascular age-related macular degeneration
    Andrea Montesel
    Ahmed M. Hagag
    Shruti Chandra
    Raheeba Pakeer Muhammed
    Sridevi Thottarath
    Swati Chandak
    Sobha Sivaprasad
    [J]. Eye, 2023, 37 : 3648 - 3655
  • [2] Aflibercept for neovascular age-related macular degeneration
    Sarwar, Salman
    Clearfield, Elizabeth
    Soliman, Mohamed Kamel
    Sadiq, Mohammad Ali
    Baldwin, Andrew J.
    Hanout, Mostafa
    Agarwal, Aniruddha
    Sepah, Yasir J.
    Do, Diana V.
    Quan Dong Nguyen
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (02):
  • [3] AFLIBERCEPT FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Verner-Cole, E. A.
    Davis, S. J.
    Lauer, A. K.
    [J]. DRUGS OF TODAY, 2012, 48 (05) : 317 - 329
  • [4] Intravitreal aflibercept for neovascular age-related macular degeneration
    Xu, David
    Kaiser, Peter K.
    [J]. IMMUNOTHERAPY, 2013, 5 (02) : 121 - 130
  • [5] Comparison of Loading Doses of Ziv-Aflibercept and Aflibercept in Neovascular Age-Related Macular Degeneration
    Ayachit, Apoorva
    Singh, Sumit Randhir
    Subramanyam, Anand
    Tiwari, Sarvesh
    Heranjal, Abhishek
    Chattannavar, Goura
    Pandey, Priti
    Salti, Haitham
    Mansour, Mohamad A.
    Mansour, Ahmad
    Chhablani, Jay
    [J]. ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2020, 9 (02): : 144 - 148
  • [6] Aflibercept for Intravitreal Injection In Neovascular Age-Related Macular Degeneration
    Frampton, James E.
    [J]. DRUGS & AGING, 2012, 29 (10) : 839 - 846
  • [7] Review of Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration
    Stewart, Michael W.
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2013, 5 : 81 - 93
  • [8] Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration
    He, Lingmin
    Silva, Ruwan A.
    Ayoub, Noel
    Moshfeghi, Darius M.
    Leng, Theodore
    [J]. OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2015, 46 (05): : 542 - 549
  • [9] Aflibercept for Intravitreal InjectionIn Neovascular Age-Related Macular Degeneration
    James E. Frampton
    [J]. Drugs & Aging, 2012, 29 : 839 - 846
  • [10] Intravitreal brolucizumab in neovascular age-related macular degeneration with limited response to aflibercept
    Hatz, Katja B.
    Cedro, Luca
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)